What’s Next For Sarepta Stock After A 12% Fall?

What’s Next For Sarepta Stock After A 12% Fall?

The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. In comparison, the broader S&P500 index…